Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEMA Fentanyl for Breakthrough Cancer Pain (FEN-202)
NCT00293020Phase 3Completed
- Sponsor
- BioDelivery Sciences International
- Start
- Feb 2006
- Primary completion
- Jun 2008
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of fentanyl in breakthrough cancer pain (BTcP), sponsored by BioDelivery Sciences International. Primary endpoint: Percentage of Participants With Adverse Events at 126 days. Started Feb 2006; status: completed.
02
Drugs
fentanyl
03
Conditions
breakthrough cancer pain (BTcP)
Beyond the preview
Go deeper on NCT00293020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00293020.